ELSEVIER

Contraception

Contraception 63 (2001) 343–344

Author Index
Volume 63
January–June 2001

Ahola, L., 19
Aleem, M., 104
Alvarez, F., 257
Alverson, M. W., 89
Amro, B. I., 329
Andersen, R. M., 277
Aragón, S., 131
Arscott, A., 65
Asthana, O. P., 47
Athayde, C., 263
Ayotte, N., 289

Baird, D. D., 211
Baird, D. T., 123
Balasinor, N., 104
Balistreri, E., 57
Barambio, S., 131
Barbosa, I., 263
Beksinska, M. E., 33
Benagiano, G., 239
Bermejo, R., 235
Bersi, C., 303
Bieber, E., 289
Biswas, A., 137
Boggress, J., 57
Bonin, E., 229
Bouchard, C., 289
Boyd, R. A., 71
Brache, V., 257
Brady, M., 267
Breaux, C., 319
Brekenfeld, C., 325
Browner, C. H., 277
Broyles, F. W., 1
Bryden, P. J., 223, 229
Bulut, A., 267, 309

Canto, P., 143
Canto De Cetina, T. E., 143
Cantuaria, A. A., 37
Carbonell, J. L. L., 131
Carlan, S. J., 89
Carmassi, F., 303
Chami, S., 131
Chandler, W. L., 1
Cheung, M., 1
Coeling Bennink, H. J. T., 137
Coll, C., 235
Coney, P. J., 297
Cook, L., 25
Costa, C. F. F., 155
Cottingham, J., 267
Coutinho, E., 263
Creasy, G. W., 289
Croxatto, H. B., 111

Darney, P., 57
Darney, P. D., 151
de Alencar Ximenes, R., 155
de Lourdes, M., 263
De Negri, F., 303
Devoto, L., 111
Dhawan, L., 95, 335
Diaz, J., 267
Dickson-Tetteh, K. E., 33
DiGiovanna, J. J., 297
Dorea, J. G., 37
Doval, J. L., 235
Dueñas, J. L., 235
Dunn, N. R., 65
Dunson, D. B., 211
Durand, M., 111

Eisinger, S., 251
Elomaa, K., 13, 257
Eriksson, C. J. P., 19
Ezcurra, E., 111

Fang, R.-Y., 283
Farley, T. M. M., 267
Faúndes, A., 155, 257
Feldblum, P. J., 159
Fener, N., 151
Fernandes Costa, L. O. B., 155
Fielding, S. L., 251
Fisher, A. C., 289
Flack, M. R., 71
Fletcher, P., 223
Fletcher, P. C., 229
Fogg, L., 319
Fruzzetti, F., 303

Gehlert, S., 319
Gelberg, L., 277
Genazzani, A. R., 303
Gharaibeh, M. N., 329
Ghosh, D., 95, 335
Gill-Sharma, M. K., 104
Glasier, A. F., 123
Gonzalez, J. A., 89
Guerra, M. O., 53
Guner, H., 151
Gupta, R. C., 47

Hampton, R. M., 289
Hapangama, D., 123
Harper, C., 57
Harrison, D. D., 297
Hartlage, S. A., 319
Harwood, B., 217, 255
Hays, M. A., 159
He, Q.-J., 283
Hendrickx, A. G., 95, 335
Hirsch, C., 263

International Collaborative Post-Marketing Surveillance of Norplant, 167, 187
Irsula, B., 159

Jackanicz, T., 257
Jain, J. K., 217, 255
Joanis, C., 267
Juneja, H. S., 104

Kadanali, S., 41
Keller, P. J., 325
Kleinschmidt, I., 33
Knopp, R. H., 1
Knudsen, U. B., 247
Koegel, P., 277
Koenig, J., 81
Komec, D., 41
Korver, T., 137

Ladipo, O. A., 263
Lähteenmäki, P., 13, 257
Lal, J., 47
Lalitkumar, P. G. L., 95, 335
Langley, R. G. B., 297
Larrea, F., 111
Lasley, B. L., 95, 335
Leake, B. D., 277
Lete, I., 235
Lopes, R., 263
Lu, M. C., 277

0010-7824/01/$ – see front matter © 2001 Elsevier Science Inc. All rights reserved.
PII: S0010-7824(01)00239-6

Marcovina, S., 1
Margulies, R., 147
Martínex-Salmeán, J., 235
Masset, J., 235
Matias, B., 263
McIntyre, J. A., 33
McMullen, S. L., 159
Meckstroth, K. R., 217, 255
Merk-Feld, G. S., 325
Migge, B., 325
Miller, L., 147
Mishell, D. R., 257
Mishell, D. R., Jr., 217, 255
Moore, K., 1
Morgenstern, H., 277
Moussa, A., 315
Mqoqi, N., 33

Nagaraja, N. V., 47
Nagle, C., 111
Nanda, K., 25
Nascimento, P., 263
Nitynand, S., 47
Noyan, V., 151

Ojeda, G., 267
Ordoñez Luna, M., 143
Ortayli, N., 267, 309
Ortiz, M., 111
Overstreet, J. W., 95, 335

Painter, R., 61
Palmore, S., 267
Parrilla, J. J., 235
Parte, P., 104
Peregoudov, A., 267
Peters, V. M., 53
Pinheiro, N. L., 53
Posvar, E. L., 71

Ramos, R., 267
Ranta, S., 13
Ratnam, S. S., 137
Rees, H. V., 33
Reis, J. E. P., 53
Ricci, C., 303
Ringheim, K., 267
Rodrigues da Cunha, A. C., 37
Rodriguez, J., 131
Rosario, J. F., 95, 335

Sahin, T., 309
Salhab, A. S., 329
Sánchez, C., 131
Sarkola, T., 19
Sawaya, G. F., 57
Schaff, E. A., 251
Sengupta, J., 95, 335
Serrano, I., 235
Shangold, G., 289
Shentu, J.-Z., 283
Shomaf, M. S., 329
Short, M., 289
Sivin, I., 309
Stadalius, L., 251
Stewart, F., 81

Tanda, R., 131
Taylor, D., 25
Thorogood, M., 65
Tiras, M. B., 151
Trussell, J., 77, 81, 211
Tuominen, J., 13

Uslu, H., 41

Valero, F., 131
Vantman, D., 111
Varoglu, E., 41
Vaughan, B., 81
Vega, M., 111
Velazco, A., 131
Vessey, M., 61
Viegas, O. A. C., 137
von der Pahlen, B., 19
von Hertzen, H., 111

Wang, L.-M., 283
Washenik, K., 297
Weinberg, C. R., 211
Welkovic, S., 155
Wenzel, S. L., 277
Wilcox, A. J., 211
Wong, V., 95, 335

Yildirim, M., 151

Zegarac, E. A., 71
Zhou, H.-J., 283

ELSEVIER

Contraception

Contraception 64 (2001) 135–137

Subject index-Corrected Volume 63 January–June 2001

Acceptability, diaphragm, 267
Alcohol, effect on ethinylestradiol + gestodene, 19
Androgenic activity, graduated ethinylestradiol doses norethindrone acetate, 71

Barrier contraceptive use, coital diary designs, 159
Benefits and risks knowledge, oral contraceptives, 223
Bioavailability,
  ethinylestradiol + gestodene, 13
  ethinylestradiol + norethisterone acetate, 13
Bleeding, effect of post-placental copper T 380A insertion, 155

Carbohydrate metabolism,
  effect of etonogestrel (3-keto-desogestrel), 137
  effect of levonorgestrel, 137
  Sickle cell patients using Uniplant, 263
Centchroman,
  dosing schedule, 47
  pharmacokinetics, 47
Cervical neoplasia risk, hormonal contraception without Pap smear, 57
Clinical study,
  emergency contraception, 111
  estradiol valerate + norethisterone enanthate, 151
  ethinylestradiol + norethindrone acetate, 297
  triphasic ethinylestradiol + norgestimate, 297
Coital diary designs, 159
Compliance, effect of counseling on use of DMPA, 143
Condom,
  eZ•on™, 25
  female, 33
  latex, 25
Contraception practices, rural vs. urban women, 319
Contraceptive attitudes, survey, 235
Contraceptive efficacy, Persona, 77
Contraceptive methods, use among homeless women, 277
Contraceptive methods use, survey, 235
Copper metabolism during lactation, effects of copper IUDs, 27
Cost comparison in family planning program, DMPA vs. oral contraceptives, 147
Counseling, effect on compliance of DMPA use, 143
Cu T-200, transport mechanisms in genital tract, 41
Cu 200B, effect on copper metabolism, 37
Cu T=-380, immediate postabortion insertion, 315
Cu T=-380A,
  effect on copper metabolism, 37
  post-placental insertion, 155
Cycle control, effect of ethinylestradiol + gestodene, 303

Depot-medroxyprogesterone acetate (DMPA), effect of counseling on compliance, 143
Diaphragm,
  acceptability, 267
  service delivery issues, 267
  use-effectiveness, 267
DL111-IT,
  effect on uterus (rat), 283
  non-hormonal contragestational agent, 283
DL111-IT + mifepristone, effect on uterine polyamines biosynthesis (rat), 283
DMPA (depot-medroxyprogesterone acetate)
DMPA use, cost increase in family planning program, 147
Dosage regimen, centchroman, 47

Ear diseases, effect of oral contraceptives, 61
Efficacy,
  intrauterine devices, 167
  Norplant implants, 167
  sterilization, 167
Emergency contraception,
  clinical studies, 111
  definition, 111
  evaluation of knowledge from media campaign, 81
  historical background, 111
  hormonal regimens, 111
  levonorgestrel, 123
  mechanism of action, 111
Endometrial thickness, following medical abortion, 255
Endometrium
  effect of fumagillin (monkey), 95
  effect of magainin (monkey), 335
Estradiol valerate + norethisterone enanthate, clinical study, 151
Estrostep^{R}, graduated ethinylestradiol doses + norethindrone acetate, 71
Ethinylestradiol + desogestrel,
  hemostatic effects, 1
  metabolic effects, 1
Ethinylestradiol + gestodene,
  bioavailability, 13
  effect of alcohol, 19
  effect on cycle control, 303
  effect on haemostasis, 303
Ethinylestradiol + levonorgestrel,
  Effect on weight and side effects, 289

0010-7824/01/$ – see front matter © 2001 Elsevier Science Inc. All rights reserved.
PII: S0010-7824(01)00240-2

hemostatic effects, 1
metabolic effects, 1
Ethinylestradiol + norethindrone acetate,
androgenic activity, 71
clinical study, 297
pharmacokinetics, 71
Ethinylestradiol + norethisterone acetate, bioavailability, 13
Ethinylestradiol + norgestimate, clinical study, 297
Etonogestrel (3-keto-desogestrel), effect on carbohydrate metabolism, 137
eZ•on™, polyurethane condom, 25

Female condom, structural integrity after multiple uses, 33
Fertility,
effect of postcoital administration of steroid (animal models), 111
effect of tamoxifen metabolites (male rat), 104
Fumagillin, effect on endometrium (monkey), 95

Hemostatic parameters,
effect of ethinylestradiol + desogestrel, 1
effect of ethinylestradiol + levonorgestrel, 1
Homeless women, use of contraceptive methods, 277
Hormonal contraception without Pap smear, cervical neoplasia risk, 57
Hormonal regimens, emergency contraception, 111
β-human chorionic gonadotropin levels, following medical abortion, 255

Immediate postabortal contraception, 309
Implanon^{R} implants
effect on carbohydrate metabolism, 137
localized by magnetic resonance imaging, 325
Implant contraceptive,
etonogestrel, 137
levonorgestrel, 137, 167, 187, 309
nomegestrol acetate, 263
Infection, effect of post-placental copper T380A insertion, 155
Injectable contraceptive,
depot-medroxyprogesterone acetate, 143, 147
estradiol valerate + norethisterone enanthate, 151
Interceptive effect, *Solanum lycocarpum* (St. Hil) (rat), 53
Intrauterine device (IUD),
Cu T-200, 41
Cu 200B, 37
Cu T-380, 315
Cu T-380A, 37, 155
non-reproductive health effects, 187
releasing levonorgestrel, 309
safety and efficacy, 167
Intrauterine instillation, quainacrine, 239
IUD (intrauterine device)

Knowledge, OC use, 229
Knowledge about emergency contraception, effect of media campaign, 81
Knowledge of risks and benefits, oral contraceptives, 223

Lactation, effect of copper IUDs on copper metabolism, 37
Latex condom, 25
Levonorgestrel,
effect on carbohydrate metabolism, 137
effect on menstrual cycle, 123
use in emergency contraception, 123
Levonorgestrel IUD, immedate postabortal contraception, 309
Lobeira fruit, interceptive effect (rat), 53
Localization of Implanon implants, use of magnetic resonance imaging, 325
Loperamide + acetaminophen prophylaxis, effect during medical abortion, 217

Magainin, effect on endometrium (monkey), 335
Magnetic resonance imaging, localization of Implanon implants, 325
Mechanism of action, emergency contraception, 111
Media campaign evaluation, emergency contraception knowledge, 81
Medical abortion,
effect of loperamide and acetaminophen prophylaxis, 217
mifepristone + misoprostol, 247, 251
misoprostol, 89, 131, 217
tamoxifen + misoprostol, 255
Meloxicam
cyclo-oxygenase-2 inhibitor, 329
effect on ovulation (rabbit), 329
Menstrual cycle, effect of levonorgestrel, 123
Metabolic effects,
ethinylestradiol + desogestrel, 1
ethinylestradiol + levonorgestrel, 1
Mifepristone, effect on uterine polyamines biosynthesis (rat), 283
Mifepristone + misoprostol, medical abortion, 247, 251
Misoprostol,
medical abortion, 131, 217
second trimester pregnancy termination, 89
Myocardial infarction, effect of OC use on outcome, 65

Nesterone® (formerly ST-1435)
Nestorone vaginal rings, effect on ovarian function, 257
Nomegestrol acetate, effect on carbohydrate metabolism, 263
Non-reproductive health effects,
intrauterine devices, 187
Norplant implants, 187
sterilization, 187
Norplant implants,
effect on carbohydrate metabolism, 137
immediate postabortal contraception, 309
non-reproductive health effects, 187
post-marketing surveillance, 167, 187
safety and contraceptive efficacy, 187

OC (oral contraceptive)
OC knowledge, survey, 223, 229
OC use,
effect on ear diseases, 61

effect on outcome following myocardial infarction, 65
university aged females, 229
Oral contraceptive (OC),
centchroman, 47
ethinylestradiol + gestodene, 13, 19, 303
ethinylestradiol + levonorgestrel, 289
ethinylestradiol + norethindrone acetate, 71, 297
ethinylestradiol + norethisterone acetate, 13
phasic ethinylestradiol + desogestrel, 1
phasic ethinylestradiol + levonorgestrel, 1
triphasic ethinylestradiol + norgestimate, 297
Outpatient second trimester pregnancy termination, misoprostol, 89
Ovarian function, effect of Nestorone vaginal rings, 257
Ovulation, effect of meloxicam (rabbit), 329

Persona,
contraceptive efficacy, 77
hormone monitoring system, 77
Pharmaceutical supply costs, family planning program, 147
Pharmacokinetics,
centchroman, 47
graduated ethinylestradiol doses + norethindrone acetate, 71
Polyurethane condom, 25
Postabortal contraception, 309
Postabortion IUD insertion, 315
Postcoital administration of steroids, effect on fertility (animal models), 111
Post-placental insertion, copper T380A, 155
Pregnancy probability, single act of intercourse, 211

Quinacrine, non-surgical female sterilization, 239

Reproductive health problems,
intrauterine devices, 167
Norplant implants, 167
sterilization, 167
Risks and benefits knowledge, oral contraceptives, 223
Rural vs. urban women, contraception practices, 319

Service delivery issues, diaphragm, 267
Sickle cell patients, carbohydrate metabolism during use of Uniplant, 263
Side effects, use of ethinylestradiol + levonorgestrel, 289
Single act of intercourse, likelihood of conception, 211
Solanum lycocarpum (St. Hil) fruit, interceptive effect (rat), 53
Sperm transport, effect of IUD, 41
Sterilization,
non-reproductive health effects, 187
quinacrine, 239
safety and efficacy, 167
Structural integrity, female condom after multiple uses, 33

Tamoxifen + misoprostol, medical abortion, 255
Tamoxifen metabolites, effect on fertility (male rat), 104
Transport mechanisms in genital tract, effect of IUD, 41

Uniplant, carbohydrate metabolism in sickle cell patients, 263
Use-effectiveness, diaphragm, 267
Uterine polyamines biosynthesis, effect of DL111-IT and mifepristone (rat), 283

Vaginal rings, releasing Nestorone, 257

Weight, effect of ethinylestradiol + levonorgestrel, 289